A preliminary examination of the multiple dimensions of opioid craving.
Content validity
Craving
Mixed-methods
Online crowdsourcing
Opioids
Journal
Drug and alcohol dependence
ISSN: 1879-0046
Titre abrégé: Drug Alcohol Depend
Pays: Ireland
ID NLM: 7513587
Informations de publication
Date de publication:
01 02 2021
01 02 2021
Historique:
received:
12
06
2020
revised:
13
11
2020
accepted:
04
12
2020
pubmed:
12
1
2021
medline:
12
5
2021
entrez:
11
1
2021
Statut:
ppublish
Résumé
Although craving is a formal DSM-5 criterion and a commonly reported feature of opioid use disorder (OUD), there is no universally accepted assessment of opioid craving for treatment outcome studies or clinical trials. This mixed-methods study characterized dimensions of opioid craving identified in qualitative responses collected via Amazon Mechanical Turk (AMT). Thirty-nine participants completed an online screener on AMT and met inclusion criteria (e.g., > = 18 years old and past 30-day illicit opioid use). These participants completed a series of closed- and open-ended questions about their opioid use and craving, including several commonly-used craving measures. They also rated their preference for how different questions described craving. Responses to the open-ended question "What do you mean when you say you are craving opioids?" were coded according to dimensions in existing opioid craving assessments and other common themes identified in the data. Among the 39 participants, 8 different dimensions were identified and coded. Descriptions of craving were most frequently categorized as "Anticipation of Negative Reinforcement" (n = 17/39) and "Interfering Thoughts" (N = 14/39). Individuals with drug use characteristics reflecting greater severity of use were more likely to describe craving as "Interfering Thoughts". Participants may prefer opioid craving questions that included Visual Analog Scale response formats relative to Likert scales. There is a wide range of dimensions that were used to describe opioid craving and no single unifying dimension was identified. These data suggest opioid craving is a multidimensional construct including dimensions currently not included in common craving assessments.
Sections du résumé
BACKGROUND
Although craving is a formal DSM-5 criterion and a commonly reported feature of opioid use disorder (OUD), there is no universally accepted assessment of opioid craving for treatment outcome studies or clinical trials. This mixed-methods study characterized dimensions of opioid craving identified in qualitative responses collected via Amazon Mechanical Turk (AMT).
METHOD
Thirty-nine participants completed an online screener on AMT and met inclusion criteria (e.g., > = 18 years old and past 30-day illicit opioid use). These participants completed a series of closed- and open-ended questions about their opioid use and craving, including several commonly-used craving measures. They also rated their preference for how different questions described craving. Responses to the open-ended question "What do you mean when you say you are craving opioids?" were coded according to dimensions in existing opioid craving assessments and other common themes identified in the data.
RESULTS
Among the 39 participants, 8 different dimensions were identified and coded. Descriptions of craving were most frequently categorized as "Anticipation of Negative Reinforcement" (n = 17/39) and "Interfering Thoughts" (N = 14/39). Individuals with drug use characteristics reflecting greater severity of use were more likely to describe craving as "Interfering Thoughts". Participants may prefer opioid craving questions that included Visual Analog Scale response formats relative to Likert scales.
CONCLUSIONS
There is a wide range of dimensions that were used to describe opioid craving and no single unifying dimension was identified. These data suggest opioid craving is a multidimensional construct including dimensions currently not included in common craving assessments.
Identifiants
pubmed: 33429294
pii: S0376-8716(20)30638-4
doi: 10.1016/j.drugalcdep.2020.108473
pmc: PMC10041947
mid: NIHMS1663085
pii:
doi:
Substances chimiques
Analgesics, Opioid
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
108473Subventions
Organisme : NIDA NIH HHS
ID : R01 DA035246
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA054101
Pays : United States
Organisme : NIDA NIH HHS
ID : R21 DA054952
Pays : United States
Organisme : NIDA NIH HHS
ID : T32 DA007209
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.
Références
Fam Relat. 2016 Oct;65(4):550-561
pubmed: 28804184
Drug Alcohol Depend. 2014 Dec 1;145:121-6
pubmed: 25454409
J Pers Assess. 2005 Oct;85(2):112-24
pubmed: 16171410
Am J Drug Alcohol Abuse. 2018;44(5):502-511
pubmed: 29634425
J Exp Anal Behav. 2018 Jul;110(1):136-153
pubmed: 29873806
Addict Behav. 2002 Sep-Oct;27(5):675-85
pubmed: 12201376
Addiction. 1998 Jul;93(7):1091-102
pubmed: 9744139
Psychol Addict Behav. 2017 Feb;31(1):85-94
pubmed: 27893213
J Consult Clin Psychol. 2013 Feb;81(1):1-12
pubmed: 23231572
Drug Alcohol Depend. 2019 Sep 1;202:200-208
pubmed: 31357121
Addict Behav. 2018 Aug;83:123-129
pubmed: 29428330
Addict Biol. 2020 Nov;25(6):e12831
pubmed: 31617639
Drug Alcohol Depend. 2019 Dec 1;205:107639
pubmed: 31683241
Psychopharmacology (Berl). 2018 Sep;235(9):2713-2723
pubmed: 29980821
Alcohol Clin Exp Res. 1995 Feb;19(1):92-9
pubmed: 7771669
Front Psychiatry. 2013 Oct 18;4:137
pubmed: 24151471
Neuropsychopharmacology. 2019 Mar;44(4):826-833
pubmed: 30375498
PLoS One. 2013;8(3):e57410
pubmed: 23516406
JAMA Psychiatry. 2019 Nov 1;76(11):1113-1114
pubmed: 31339512
Exp Clin Psychopharmacol. 2019 Feb;27(1):1-18
pubmed: 30489114
Neuropsychopharmacology. 2010 Jan;35(1):217-38
pubmed: 19710631
Trials. 2018 Dec 10;19(1):675
pubmed: 30526648
Addict Behav. 2018 Jul;82:72-78
pubmed: 29499393
Lancet. 2018 Jan 27;391(10118):309-318
pubmed: 29150198
Arch Gen Psychiatry. 2009 Jan;66(1):88-94
pubmed: 19124692
J Subst Abuse Treat. 2006 Dec;31(4):355-64
pubmed: 17084789
Physiol Rev. 2019 Oct 1;99(4):2115-2140
pubmed: 31507244
Drug Alcohol Depend. 2013 Dec 1;133(2):661-8
pubmed: 24071571
Am J Psychiatry. 2019 Nov 1;176(11):911-922
pubmed: 31109198
Annu Rev Clin Psychol. 2016;12:53-81
pubmed: 26772208
Psychopharmacology (Berl). 2001 Mar 1;154(2):153-60
pubmed: 11314677
Front Psychiatry. 2019 Aug 30;10:592
pubmed: 31543832
Perspect Psychol Sci. 2011 Jan;6(1):3-5
pubmed: 26162106
NCHS Data Brief. 2018 Nov;(329):1-8
pubmed: 30500323
Neurotherapeutics. 2020 Jan;17(1):100-104
pubmed: 31650431
Addict Behav. 2015 Feb;41:20-8
pubmed: 25282598